Artesunate for injection

Artesunate for injection

Larinate® 60mg for injection
Severe malaria treatment (TPP-1)
Therapeutic indication
  • Treatment of severe malaria caused by the parasite P. falciparum, to be followed by a full course of ACT

  • At least three injections within 1 day during critical phase

  • 92% survival vs 88% survival with quinine in African children

  • Coma duration, convulsions, and hypoglycaemia significantly lower with artesunate compared to quinine

Key features
  • Increased global supply of artesunate for injection

  • Cost per disability-adjusted life year (DALY) averted: US$ 3.8

  • 3-year shelf life

  • Potential for delayed haemolytic anaemia

  • Continued use of quinine or artemether for injection

  • Must be followed up with ACT to avoid artemisinin monotherapy use
  • WHO prequalification in 2018
  • Approved in 25 countries; 26.7 million Larinate® 60mg vials shipped since prequalification up to and including 2022
Next milestone
  • Simplified injectable artesunate two-vial formulation currently under review for WHO prequalification review

  • Additional country registrations

Project Director
  • Hans Rietveld